Please upgrade your browser.
Eisai Co., Ltd. announced today the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma.
Immunotherapy seeks to expose tumours to the cancer-killing power of the human immune system. It was declared “Breakthrough of the Year” by the journal Science in December 2013.
Arginase is an enzyme in myeloid-derived suppressor cells (MDSCs), which prevents T-cell and natural killer (NK) cell activation in tumors.
The new dosage regimen is for 240mg IV every 2 weeks until disease progression or intolerable toxicity for renal cell carcinoma...
Bi-allelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Cell lines (CAKI-1, HK2 or A704) were either transfected with 2 independent siRNAs or non-target controls.
The drug, cabometyx, is approved for patients in advanced stages of the disease who have already received prior treatment. The drug was approved by the U.S.'s Food and Drug Administration in April.
Advanced tumors may have met their match with new drugs, but why have these treatments proved ineffective at stopping early-stage tumors from coming back?
Siegel hopes that these findings will encourage investigators to find out the "driving forces behind these increases."
In rare circumstances, a person with sickle cell trait may develop a rare kidney cancer called renal medullary carcinoma.
High BMI is a prognostic factor for improved survival and progression-free survival in patients with metastatic RCC...
|Powered by NeonCRM|